Table 4.
Clinical Response by Baseline Pathogen
| Pathogen | Omadacycline (n = 504) | Linezolid (n = 514) |
|---|---|---|
| Staphylococcus aureus, n | 376 | 384 |
| ECR | 332 (88.3) | 325 (84.6) |
| IACR-PTE | 312 (83.0) | 312 (81.3) |
| MRSA, n | 173 | 157 |
| ECR | 159 (91.9) | 139 (88.5) |
| IACR-PTE | 146 (84.4) | 128 (81.5) |
| MSSA, n | 208 | 232 |
| ECR | 178 (85.6) | 190 (81.9) |
| IACR-PTE | 171 (82.2) | 187 (80.6) |
| Streptococcus pyogenes, n | 40 | 34 |
| ECR | 32 (80.0) | 30 (88.2) |
| IACR-PTE | 28 (70.0) | 25 (73.5) |
| Staphylococcus lugdunensis, n | 11 | 3 |
| ECR | 10 (90.9) | 3 (100.0) |
| IACR-PTE | 10 (90.9) | 2 (66.7) |
| Enterococcus faecalis, n | 18 | 25 |
| ECR | 16 (88.9) | 20 (80.0) |
| IACR-PTE | 17 (94.4) | 21 (84.0) |
| Enterobacter cloacae, n | 8 | 7 |
| ECR | 8 (100.0) | 6 (85.7) |
| IACR-PTE | 7 (87.5) | 7 (100.0) |
| Klebsiella pneumoniae, n | 11 | 11 |
| ECR | 10 (90.9) | 9 (81.8) |
| IACR-PTE | 8 (72.7) | 6 (54.5) |
| Streptococcus anginosus group, na | 104 | 82 |
| ECR | 93 (89.4) | 63 (76.8) |
| IACR-PTE | 84 (80.8) | 59 (72.0) |
Data are presented as No. (%) and are from the micro-mITT population. Baseline pathogens were identified by culture of blood or ABSSSI site specimens. An acceptable ABSSSI site specimen was defined as a specimen obtained from a biopsy of involved cutaneous or subcutaneous tissue, preferably from the advancing margin of the lesion; debrided tissue; tissue scraping (using curette or scalpel); needle aspirate of involved, nonpurulent cutaneous or subcutaneous tissue; pus or infected tissue collected during an incision and drainage procedure; or pus aspirated into a syringe or a deep swab of purulent material (only if collected from infected tissue that had been incised or was draining). Surface swabs of wounds, inflamed skin, or drainage (including purulent material) were not considered valid sampling techniques.
Abbreviations: ABSSSI, acute bacterial skin and skin structure infections; ECR, early clinical response; IACR, investigator-assessed clinical response; micro-mITT, all modified intent-to-treat patients who had ≥1 causative pathogen; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PTE, posttreatment evaluation.
aThe Streptococcus anginosus group consists of S. anginosus, S. intermedius, and S. constellatus.